Skip to content
Therapy But Better – Lifestyle
Author:
AEON Biopharma Inc
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
June 4, 2026
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
AEON Biopharma Sets Annual Shareholder Meeting
April 24, 2026
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
April 6, 2026
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
April 3, 2026
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
March 31, 2026
AEON Biopharma Appoints John Bencich as Chief Financial Officer
March 26, 2026
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
March 25, 2026